Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine
Summary
The poster entitled Pharmacodynamic and Tumor Biomarker Analysis of a PLK1 Inhibitor, PCM-075, in a Phase 1b/2 Trial for Acute Myeloid Leukemia presents the methodology developed to track dynamic changes in blood leukemic cells, genomic alterations and PLK1 inhibition in AML patients treated with PCM-075 in combination with LDAC."We are pleased with the progress we are making in our Phase 1b/2 AML study and the collaboration and support we are receiving from our investigators," said Bill Welch, Chief Executive Officer of Trovagene.Trovagene has broad intellectual property and proprietary technology to analyze circulating tumor DNA (ctDNA) and clinically actionable biomarkers to identify patients most likely to respond to specific cancer therapies.PCM-075 has demonstrated synergy in preclinical studies with over 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including FLT3 and HDAC inhibitors, taxanes, and cytotoxins.These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Trovagenes expectations, strategy, plans or intentions.